Jul 8, 2021 | CMT Research Updates, CMTRF Funded Research, Drug Development, News, Research news, Small Molecule Therapies, Therapy Types
The CMT Research Foundation is partnering with the University of Illinois Chicago to test a potential therapeutic for CMT1X, the second most common form of CMT, behind only CMT1A in prevalence. CMT is one of the most common inherited neurological disorders, affecting...
Jun 27, 2021 | About CMT, CMT Research Updates, CMTRF Funded Research, Drug Development, Small Molecule Therapies, Therapy Types
The CMT Research Foundation is proud to announce our latest project, a partnership between AcuraStem, a patient-based drug discovery platform company, and Dr. Alessandra Bolino, a renowned expert in CMT and the head of the Human Inherited Neuropathies Unit at the...
Jan 7, 2020 | CMT Research Updates, Research news, Small Molecule Therapies, Therapy Types
Can axon degeneration be prevented in CMT? By Dr. Grace Pavlath, PhD I’m often asked if a therapy for one type of CMT could be beneficial in another. There are over 100 different genes known to cause CMT; they either directly disrupt myelin or axon integrity of...
Sep 18, 2019 | CMT Research Updates, Press Releases, Research news, Small Molecule Therapies, Uncategorized
Just nine months ago, we announced a milestone-based, research collaboration with AcuraStem to test thousands of compounds aimed at producing effective treatments for CMT2A. We are very pleased to report that AcuraStem has completed phase one of the CMT2A project. To...
Aug 2, 2019 | CMT Research Updates, Press Releases, Research news, Small Molecule Therapies
Paving pathways for mission critical projects CMT Research Foundation is partnering with Dr. Maurizio D’Antonio of I.R.C.C.S. Ospedale San Raffaele, in Milan, Italy to fund the lab’s research of Myelin Protein Zero (MPZ), the gene associated with CMT1B. Dr....
Feb 11, 2019 | CMT Research Updates, Research news, Small Molecule Therapies
The FDA Grants Fast Track Designation to Pharnext’s PXT3003 for CMT1A Pharnext, an advanced clinical-stage biopharmaceutical company, created a drug combination of three drugs: baclofen, naltrexone and sorbitol known as PXT3003. Baclofen is known to relieve...
Important Research News Announcements